Trial Profile
An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories
- 23 Mar 2011 Lead trial investigator (Konstantin Gudkov) added as reported by ClinicalTrials.gov.
- 23 Mar 2011 Actual end date changed from 1 Apr 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.
- 11 Nov 2010 New trial record